title: The Metabolomic Strategy in Tuberculosis Therapy.
abstract: Tuberculosis causes around 1.4 million deaths every year remaining to be a major cause of morbidity and mortality. Mycobacterium tuberculosis is adept at surviving the assault of our immune system, which has perplexed many researchers. Not only are they difficult to treat, but also difficult to detect accurately. The current reservoir of drugs and method to diagnose them is depleting faster than we are able to replace them with newer one. The advances made in the field of metabolomic have opened up a window of opportunities such as identification of new drug and druggable site, prediction of drug toxicity and detection of new biomarkers to accurately diagnose the disease. With its short history of less than two decades, metabolomics has shown very promising future to tackle this concern. Equally important developments in analytical techniques and application of data interpretation have further facilitated the scope of this field. The present review discusses the advances in metabolomic research with an emphasis on tuberculosis diagnosis and therapeutics.
authors.affiliation: Indian Institute of Technology, Guwahati, Assam, India.
authors.forename: Nitendra
authors.initials: N
authors.lastname: Kumar
authors.affiliation: Kathmandu University,Dhulikhel, Nepal.
authors.forename: Ashwinee Kumar
authors.initials: AK
authors.lastname: Shreshtha
authors.affiliation: Indian Institute of Technology, Guwahati, Assam, India.
authors.forename: Sanjukta
authors.initials: S
authors.lastname: Patra
mesh_terms: D000995:Antitubercular Agents; D015415:Biomarkers; D006801:Humans; D055432:Metabolomics / Q000379:methods* / Q000639:trends; D014376:Tuberculosis / Q000175:diagnosis / Q000628:therapy*
chemical_list: D000995:Antitubercular Agents; D015415:Biomarkers
keywords: MS; Metabolomic; NMR; Tuberculosis; biomarker; drug discovery